Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories, Inc. (MLAB) provides critical quality control solutions for pharmaceutical, healthcare, and life sciences industries through its sterilization monitoring, calibration systems, and biopharmaceutical development tools. This page aggregates official press releases and verified news updates essential for tracking the company’s operational and regulatory developments.
Investors and industry professionals will find timely updates on earnings reports, product launches, regulatory milestones, and strategic partnerships. All content is sourced directly from the company or reputable financial publications to ensure accuracy in this fast-moving sector.
Key focus areas include innovations in sterilization validation technologies, advancements in clinical genomics tools, and updates to compliance standards affecting medical device manufacturing. The curated collection serves as a reliable resource for understanding how MLAB addresses evolving challenges in quality assurance for regulated environments.
Bookmark this page for streamlined access to Mesa Laboratories’ latest developments, or check back regularly to stay informed about this essential player in life sciences infrastructure.
Mesa Laboratories (NASDAQ:MLAB) has announced a quarterly dividend declaration of $0.16 per share of common stock. The dividend will be distributed on June 16, 2025, to shareholders recorded as of May 30, 2025.
Mesa Labs, a global leader in life science tools and critical quality control solutions, serves the pharmaceutical, healthcare, and medical device industries. The company focuses on ensuring product integrity, increasing patient and worker safety, and improving quality of life worldwide through their specialized products and services.
Mesa Laboratories (NASDAQ:MLAB) reported strong Q3 FY2025 results with revenues increasing 17.5% to $62,840,000. The company achieved 13.2% core organic revenue growth and an 8,725% increase in operating income to $5,779,000. Despite operational improvements, Mesa reported a net loss of $1,676,000 primarily due to unrealized foreign currency losses and interest expense.
Performance across divisions showed positive momentum: Sterilization and Disinfection Control (37% of revenues) grew 8.2% core organic, Calibration Solutions (23%) achieved 18.9% growth, Biopharmaceutical Development (20%) saw 31.3% growth, and Clinical Genomics (20%) posted 1.9% growth. The company reduced its debt by $9.4M during the quarter, lowering its Total Net Leverage Ratio to 3.20, with a target to reduce it below 3.0x by end of Q2 2026.
Mesa Laboratories (NASDAQ:MLAB) has announced it will release its third quarter fiscal year 2025 financial results on Tuesday, February 4, 2025, at approximately 8:00 A.M. Eastern time. Mesa Labs is a global leader specializing in life science tools and critical quality control solutions for regulated applications across pharmaceutical, healthcare, and medical device industries. Their products and services focus on ensuring product integrity, enhancing patient and worker safety, and improving global quality of life.
Mesa Laboratories (NASDAQ:MLAB) has announced its Board of Directors' declaration of a regular quarterly dividend of $0.16 per share of common stock. The dividend will be paid on March 17, 2025, to shareholders of record as of the close of business on February 28, 2025.
Mesa Labs operates as a global leader in designing and manufacturing life science tools and critical quality control solutions, primarily serving regulated applications in the pharmaceutical, healthcare, and medical device industries. Their products and services aim to ensure product integrity, enhance patient and worker safety, and improve quality of life worldwide.
Mesa Laboratories (NASDAQ:MLAB) reported Q2 FY2025 results with revenues increasing 8.8% to $57,833,000, primarily driven by 11% growth from the GKE acquisition. Operating income surged 5,947% to $3,508,000, while net income increased 379%. The company experienced a 2.8% decline in core organic revenues. Notable division performance included Sterilization and Disinfection Control (38% of revenues) declining 5.2% in core organic growth, while Biopharmaceutical Development showed strong growth of 27.9%. The company reduced its debt by $7,438,000, bringing the Net Leverage Ratio to 3.26.
Mesa Laboratories, Inc. (NASDAQ:MLAB) has announced a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.
Mesa Labs is a global leader in designing and manufacturing life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. The company's products and services aim to ensure product integrity, increase patient and worker safety, and improve quality of life worldwide.
Mesa Laboratories (NASDAQ:MLAB) reported strong Q1 FY2025 results, with revenues increasing 14.9% to $58,170,000 and core organic revenues growth of 3.0%. Operating income surged 940%, while non-GAAP adjusted operating income excluding unusual items rose 47.0% to $15,341,000 or 26.4% of revenues. The company saw growth across most divisions, with Biopharmaceutical Development leading at 23.5% core organic growth. However, Clinical Genomics faced headwinds in China and North America. Mesa Labs repaid $9.4 million in debt, reducing its Net Leverage Ratio to 3.41. The company remains focused on driving profitability and reducing debt, aiming for a ratio below 3.0x.
Mesa Laboratories (NASDAQ: MLAB) has announced a quarterly dividend of $0.16 per share of common stock. The dividend is scheduled for payment on September 16, 2024, to shareholders who are on record as of August 30, 2024.
Mesa Laboratories specializes in designing and manufacturing life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries. The company's products and services aim to ensure product integrity, enhance patient and worker safety, and improve global quality of life.
Mesa Laboratories (NASDAQ: MLAB) reported its fourth quarter and full fiscal year 2024 results. In 4Q24, revenues rose by 6% compared to 4Q23, reaching $58,904, driven by the acquisition of GKE China. However, core organic revenues fell by 3.5%. The company also registered an operating loss of $271,284, due to a significant non-cash impairment charge. Non-GAAP adjusted operating income surged by 26.3%.
For FY24, revenues decreased by 1.3% to $216,187, with core organic revenues dropping 5.4%. The year saw an operating loss of $272,075. Non-GAAP adjusted operating income grew by 0.7%. Mesa Labs' financial performance was impacted by economic slowdowns and headwinds in the biopharmaceutical and clinical genomics sectors, despite gains in other areas and effective cost control measures.
Mesa Laboratories (NASDAQ: MLAB) announced a delay in issuing its unaudited fourth quarter and full fiscal year 2024 financial results, initially scheduled for today. The delay is due to the finalization of year-end audit calculations and technical accounting for previously announced impairments in its Clinical Genomics and Biopharmaceutical Development divisions, as well as purchase accounting for GKE's acquisition. The Form 10-K filing deadline with the SEC is June 14, 2024. Mesa Laboratories is a global leader in life sciences tools and quality control solutions for regulated pharmaceutical, healthcare, and medical device industries.
